Unnecessary Endoscopies Could Be Avoided with Fecal Blood Test
By LabMedica International staff writers Posted on 14 Oct 2016 |

Image: The Quantum Blue rapid test allow for the immediate measurement of fecal calprotectin (Photo courtesy of Bühlmann Laboratories).
The majority of primary care patients referred for bowel endoscopy do not have significant colorectal disease (SCD), and are unnecessarily exposed to a small but realistic risk of severe endoscopy-associated complications.
Serious colorectal diseases, including colorectal cancer, are difficult to diagnose as the signs and symptoms are not always clear. Any suspicion of SCD requires a general practitioner referral to a hospital for an endoscopy but studies have shown that between 60% to 80% of referred patients end up not having SCD.
Scientists at the University Medical Center Utrecht (Netherlands) collected data from the large-scale study where 810 patients suspected of SCD were enrolled from 266 primary care practices in the Netherlands. A pre-endoscopy venous blood sample was drawn to estimate hemoglobin and C-reactive protein (CRP) concentrations according to routine clinical practice. The team developed a diagnostic strategy to better exclude SCD in these patients and evaluated the value of adding a fecal calprotectin point-of-care (POC) and/or a POC fecal immunochemical test for hemoglobin (FIT-Hb)) to routine clinical information.
The investigators analyzed the fecal samples for calprotectin concentration by a quantitative point-of-care (POC) test (Quantum Blue; dynamic range 30 to 300 μg/g) and by an enzyme-linked immunosorbent assay (ELISA; EK-CAL Calprotectin ELISA, (both from Bühlmann Laboratories, Schönenbuch, Switzerland), both yielding estimates of μg calprotectin/g feces. For fecal Hb the team used a qualitative POC FIT, the Clearview iFOBT One Step Fecal Occult Blood Test Device, (Alere Health; Waltham, MA, USA), yielding either a positive or negative test result with a lower detection limit of 6 μg/g.
Out of the 810 patients referred for an endoscopy, 669 were found to have no SCD. Once the results of the FIT test had been taken into account the scientists found that approximately 30% of these patients could have been prevented from having an endoscopy as they may have been correctly diagnosed as not having SCD during their doctor’s visit. The study also looked at the benefit of adding a fecal test for the protein calprotectin to the diagnostic strategy. They found that this test also improved the diagnosis of SCD but not to the same extent as FIT. Furthermore, combining both tests added little extra benefit to the diagnostic accuracy of FIT alone.
The authors concluded that FIT and to a much lesser extent calprotectin POC testing showed incremental value for SCD diagnosis beyond standard clinical information. A diagnostic strategy with routine clinical data and a POC FIT test may safely rule out SCD and prevent unnecessary endoscopy referral in approximately one third of SCD-suspected primary care patients. The study was published on September 26, 2016, in the journal BMC Medicine.
Related Links:
University Medical Center Utrecht
Bühlmann Laboratories
Alere Health
Serious colorectal diseases, including colorectal cancer, are difficult to diagnose as the signs and symptoms are not always clear. Any suspicion of SCD requires a general practitioner referral to a hospital for an endoscopy but studies have shown that between 60% to 80% of referred patients end up not having SCD.
Scientists at the University Medical Center Utrecht (Netherlands) collected data from the large-scale study where 810 patients suspected of SCD were enrolled from 266 primary care practices in the Netherlands. A pre-endoscopy venous blood sample was drawn to estimate hemoglobin and C-reactive protein (CRP) concentrations according to routine clinical practice. The team developed a diagnostic strategy to better exclude SCD in these patients and evaluated the value of adding a fecal calprotectin point-of-care (POC) and/or a POC fecal immunochemical test for hemoglobin (FIT-Hb)) to routine clinical information.
The investigators analyzed the fecal samples for calprotectin concentration by a quantitative point-of-care (POC) test (Quantum Blue; dynamic range 30 to 300 μg/g) and by an enzyme-linked immunosorbent assay (ELISA; EK-CAL Calprotectin ELISA, (both from Bühlmann Laboratories, Schönenbuch, Switzerland), both yielding estimates of μg calprotectin/g feces. For fecal Hb the team used a qualitative POC FIT, the Clearview iFOBT One Step Fecal Occult Blood Test Device, (Alere Health; Waltham, MA, USA), yielding either a positive or negative test result with a lower detection limit of 6 μg/g.
Out of the 810 patients referred for an endoscopy, 669 were found to have no SCD. Once the results of the FIT test had been taken into account the scientists found that approximately 30% of these patients could have been prevented from having an endoscopy as they may have been correctly diagnosed as not having SCD during their doctor’s visit. The study also looked at the benefit of adding a fecal test for the protein calprotectin to the diagnostic strategy. They found that this test also improved the diagnosis of SCD but not to the same extent as FIT. Furthermore, combining both tests added little extra benefit to the diagnostic accuracy of FIT alone.
The authors concluded that FIT and to a much lesser extent calprotectin POC testing showed incremental value for SCD diagnosis beyond standard clinical information. A diagnostic strategy with routine clinical data and a POC FIT test may safely rule out SCD and prevent unnecessary endoscopy referral in approximately one third of SCD-suspected primary care patients. The study was published on September 26, 2016, in the journal BMC Medicine.
Related Links:
University Medical Center Utrecht
Bühlmann Laboratories
Alere Health
Latest Pathology News
- AI Tool Enhances Interpretation of Tissue Samples by Pathologists
- AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
- Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
- New Lab Model to Help Find Treatments for Aggressive Blood Cancer
- AI-Supported Microscopy Improves Detection of Intestinal Parasite Infections
- AI Performs Virtual Tissue Staining at Super-Resolution
- AI-Driven Preliminary Testing for Pancreatic Cancer Enhances Prognosis
- Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
- Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
- Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
- Advances in Monkeypox Virus Diagnostics to Improve Management of Future Outbreaks
- Nanoneedle-Studded Patch Could Eliminate Painful and Invasive Biopsies
- AI Cancer Classification Tool to Drive Targeted Treatments
- AI-Powered Imaging Enables Faster Lung Disease Treatment
- New Laboratory Method Speeds Diagnosis of Rare Genetic Disease
- New Technology Autonomously Detects AI Hallucinations in Digital Pathology
Channels
Molecular Diagnostics
view channel
Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. The symptoms of Lyme disease, such as fever, headache, fatigue,... Read more
Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
Detecting and diagnosing cancer, particularly in its early stages, remains a significant challenge. Liquid biopsies offer a promising non-invasive alternative to traditional biopsies, which require removing... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read morePathology
view channel
AI Tool Enhances Interpretation of Tissue Samples by Pathologists
Malignant melanoma, a form of skin cancer, is diagnosed by pathologists based on tissue samples. A crucial aspect of this process is estimating the presence of tumor-infiltrating lymphocytes (TILs), immune... Read more
AI-Assisted Technique Tracks Cells Damaged from Injury, Aging and Disease
Senescent cells, which stop growing and reproducing due to injury, aging, or disease, play a critical role in wound repair and aging-related diseases like cancer and heart disease. These cells, however,... Read more
Novel Fluorescent Probe Shows Potential in Precision Cancer Diagnostics and Fluorescence-Guided Surgery
Hepatocellular carcinoma (HCC), a common type of liver cancer, is difficult to diagnose early and accurately due to the limitations of current diagnostic methods. Glycans, carbohydrate structures present... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more
AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases
The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. These gut bacteria produce a variety of metabolites... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more